Biopharma
ByCan Johnson & Johnson Hit $100 Billion in Revenue Despite U.S. Pricing Pressures?
23 January 2026 Executive Summary Johnson & Johnson (J&J) has issued a bullish 2026 revenue forecast, projecting nearly…
FDA Grants Breakthrough Therapy Status to Lilly’s Folate Receptor-Targeted Ovarian Cancer Candidate
23 January 2026 Executive Summary Eli Lilly announced that the U.S. Food and Drug Administration (FDA) has granted…
Despite Geopolitical Tensions, U.S.–China Biotech Interdependence Remains Central
23 January 2026 Executive Summary Industry reports continue to underscore the deep interdependence between U.S. and Chinese biotech…
Is the U.S. Reopening the Door to Coverage Losses? ACA Subsidy Expiration Fuels Cost and Enrollment Uncertainty
23 January 2026 Executive Summary The expiration of enhanced Affordable Care Act (ACA) subsidies is continuing to drive…
Acadia’s Daybue CHMP Fight: $2B Rett Revenue at Stake or EMA Brick Wall?
Acadia Pharmaceuticals on March 3, 2026, fired back at CHMP’s rejection of Daybue (trofinetide) expansion into granular symptom…
Sanofi’s $1.53B Sino Biopharm Pact: Strategic Power Play or China-Derisked Bet?
Sanofi’s March 3, 2026, licensing of Sino Biopharm’s rovadicitinib—a JAK1 inhibitor approved in China for first-line myelofibrosis—upfront $135M…
